TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients

Exclusion Criteria

• •1. Active central nervous system (CNS) metastases. Patients with stable CNS metastases ≥ 1 month after definitive treatment (eg, surgery and/or radiotherapy) are eligible.
• •2. Participants with an active second malignancy.
• •3. Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol, including autoimmune or immunodeficient conditions, significant pulmonary disease, significant cardiac and/or vascular disease per investigator's judgment.
• •4. Prior immune-related adverse events that would preclude re-challenge with an immune checkpoint inhibitor or immunomodulatory agent per investigator's judgment.
• •5. Immunosuppressive treatment that would preclude the patient from any of the study therapies per investigator's judgment.
• •6. Severe active infections or uncontrolled infectious conditions requiring treatment.
• •7. Any other conditions/diseases, allergies, dysfunctions, and/or findings, that would contraindicate the use of any of the study interventions or therapies.
• •8. Contraindication for any of the planned measures, interventions and/or treatments.
• •9. Pregnant or breastfeeding women, or female subject who are not willing to use an acceptable, highly effective method of contraception until the End-of-Study visit.
• •10. Known hypersensitivity to any of study therapies or drugs used for TIL production.
• •11. Known human immunodeficiency virus (HIV) infection (or tests positive for HIV 1 or 2 at Screening).
• •12. Known hepatitis B or hepatitis C infection.